3570 NEW ZEALAND GAZETTE No. 121

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

---|---|---|---
Oestradiol 7.8 mg | Transdermal patch | 3M Pharmaceuticals, Northridge, California, United States of America and 3M Pharmaceuticals, St Paul, Minnesota, United States of America | Climara Forte
Sodium bicarbonate 81.25 g/l (Cobe machine), sodium bicarbonate 66.0 g/l and sodium chloride 23.5 g/l (Gambro/Drake or Willock/Baxter machines) | Dialysis solution | Ajax Chemicals, Smithfield, New South Wales, Australia | Concentrated Bicarbonate Haemodialysis Solution - Part/Component B
Dorzolamide hydrochloride 2% (22.3 mg/ml equivalent to 20 mg dorzolamide) | Ophthalmic solution | Laboratoires Merck Sharp & Dohme-Chibret, Clermont, Clermont Ferrand, France | Trusopt
Lenograstim 263 mcg (33.6 million IU) | Powder for injection | Chugai Pharmaceuticals Company Limited, Ukima Plant, Tokyo, Japan | Granocyte
Famciclovir 250 mg | Tablet | SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex, England | Famvir

Dated this 11th day of November 1994.
D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.

go8289

Consent to the Distribution of a New Related Product

Pursuant to section 96 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related product set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

---|---|---|---
Lecithin 290 mg, d-alpha tocopheryl acetate 22 mg | Chewable tablet | Nutrilite Products Inc., Buena Park, California, United States of America | Nutriway Lecithin-E

Dated this 11th day of November 1994.
D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.

go8290

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

---|---|---|---
Zalcitabine 0.375 mg, 0.75 mg | Tablets | Hoffmann-La Roche Inc., Nutley, New Jersey, United States of America | Hivid

This medicine may only be distributed, supplied or used under conditions to be imposed from time to time by the Director-General of Health.

Note: This consent is effective from 17 December 1994.

Dated this 11th day of November 1994.
D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.

go8292

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

---|---|---|---
Omeprazole 20 mg | Capsule | Astra Pharmaceutical production AB, Södertälje, Sweden | Losec
Omeprazole sodium 42.6 mg in 10 ml (equivalent to 40 mg omeprazole) | Powder for reconstitution for IV injection | Astra Pharmaceutical production AB, Södertälje, Sweden | Losec